We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellectricon Launches Outsourced Discovery Services to Enhance Research into Cytoskeletal Disturbances
Product News

Cellectricon Launches Outsourced Discovery Services to Enhance Research into Cytoskeletal Disturbances

Cellectricon Launches Outsourced Discovery Services to Enhance Research into Cytoskeletal Disturbances
Product News

Cellectricon Launches Outsourced Discovery Services to Enhance Research into Cytoskeletal Disturbances


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cellectricon Launches Outsourced Discovery Services to Enhance Research into Cytoskeletal Disturbances"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellectricon, a leading provider of advanced cell-based screening technologies, today announced the launch of its Discovery Services division. The new services offer pharma/biotech companies and CROs cutting-edge phenotypic screening support, accelerating drug discovery and cell-based assay research into cytoskeletal disturbances – especially for chronic pain.

Cellectricon’s Discovery Services aim to help drug discovery teams shorten lead development times and reduce costs. With leading expertize in assay development and screening, Cellectricon’s Discovery Services team provides fully collaborative support, tailored to each individual study. The entire services process is highly interactive, and guarantees all partners are well informed via frequent reports on assay performance, observations and progress, to ensure project goals are fully realized.

Announcing the new offering, Dr Paul Karila, Head of Cellectricon’s Discovery Services, said: “Our Cellaxess Elektra discovery platform is ideal for compound profiling in excitable primary cells and native tissue using transfection and specific electric field stimulation (EFS). With our platform, we can help researchers identify phenotypic effects in highly relevant biological models early enough in a project’s lifecycle to add real value to the decision of whether to pursue or eliminate a compound, which translates to considerable cost savings in the drug development business.”

Advertisement